0000000000209958

AUTHOR

Henrik Gensicke

showing 7 related works from this author

Safety and Outcome of Revascularization Treatment in Patients With Acute Ischemic Stroke and COVID-19: The Global COVID-19 Stroke Registry.

2023

Background and ObjectivesCOVID-19–related inflammation, endothelial dysfunction, and coagulopathy may increase the bleeding risk and lower the efficacy of revascularization treatments in patients with acute ischemic stroke (AIS). We aimed to evaluate the safety and outcomes of revascularization treatments in patients with AIS and COVID-19.MethodsThis was a retrospective multicenter cohort study of consecutive patients with AIS receiving intravenous thrombolysis (IVT) and/or endovascular treatment (EVT) between March 2020 and June 2021 tested for severe acute respiratory syndrome coronavirus 2 infection. With a doubly robust model combining propensity score weighting and multivariate regress…

Fibrinolytic Agents/therapeutic useCerebral Hemorrhage/complicationsStroke/epidemiologyBrain Ischemia/complicationsTreatment OutcomeIschemic Stroke/epidemiologyCOVID-19/complicationsHumansCohort studiesEndovascular Procedures/adverse effectsRegistriesNeurology (clinical)610 Medicine & healthIntracranial Hemorrhages/etiologyThrombolytic Therapy/adverse effectsResearch Article
researchProduct

Second asymptomatic carotid surgery trial (ACST-2): a randomised comparison of carotid artery stenting versus carotid endarterectomy.

2021

Summary Background Among asymptomatic patients with severe carotid artery stenosis but no recent stroke or transient cerebral ischaemia, either carotid artery stenting (CAS) or carotid endarterectomy (CEA) can restore patency and reduce long-term stroke risks. However, from recent national registry data, each option causes about 1% procedural risk of disabling stroke or death. Comparison of their long-term protective effects requires large-scale randomised evidence. Methods ACST-2 is an international multicentre randomised trial of CAS versus CEA among asymptomatic patients with severe stenosis thought to require intervention, interpreted with all other relevant trials. Patients were eligib…

Malemedicine.medical_specialtyTime FactorsTime Factormedicine.medical_treatmentCarotid StenosiMEDLINECarotid endarterectomyRate ratioRisk AssessmentAsymptomaticlaw.inventionRandomized controlled triallawRisk Factorscarotid artery stenting (CAS); carotid endarterectomy (CEA)StentmedicineHumansCarotid StenosisStrokeEndarterectomyAgedEndarterectomy Carotidbusiness.industrycarotid arteryRisk FactorArticlesGeneral Medicinetrialmedicine.diseaseSettore MED/22 - CHIRURGIA VASCOLARESurgeryStrokeStenosisTreatment Outcomecarotid artery stenting (CAS)Settore MED/11 - MALATTIE DELL'APPARATO CARDIOVASCOLAREFemaleStentsHuman medicinemedicine.symptomcarotid endarterectomy (CEA)businessHumanLancet (London, England)
researchProduct

Intravenous thrombolysis for suspected ischemic stroke with seizure at onset

2019

Objective Seizure at onset (SaO) has been considered a relative contraindication for intravenous thrombolysis (IVT) in patients with acute ischemic stroke, although this appraisal is not evidence based. Here, we investigated the prognostic significance of SaO in patients treated with IVT for suspected ischemic stroke. Methods In this multicenter, IVT-registry-based study we assessed the association between SaO and symptomatic intracranial hemorrhage (sICH, European Cooperative Acute Stroke Study II definition), 3-month mortality, and 3-month functional outcome on the modified Rankin Scale (mRS) using unadjusted and adjusted logistic regression, coarsened exact matching, and inverse probabil…

0301 basic medicineMalemedicine.medical_specialtymedicine.medical_treatmentLogistic regressionGUIDELINESCLASSIFICATION3124 Neurology and psychiatryBrain IschemiaEARLY MANAGEMENT03 medical and health sciences0302 clinical medicineALTEPLASEModified Rankin ScaleSeizuresMIMICSInternal medicineMedicineHumansThrombolytic TherapyPLASMINOGEN-ACTIVATOR610 Medicine & healthStrokeContraindicationPOPULATIONAgedAged 80 and overHEALTH-CARE PROFESSIONALSbusiness.industryConfounding3112 NeurosciencesOdds ratioThrombolysisASSOCIATIONMiddle Agedmedicine.diseasePrognosisConfidence intervalStroke030104 developmental biologyTreatment OutcomeNeurologySAFETYFemaleNeurology (clinical)business030217 neurology & neurosurgery
researchProduct

Recanalization Therapies in Acute Ischemic Stroke Patients Impact of Prior Treatment With Novel Oral Anticoagulants on Bleeding Complications and Out…

2015

Background— We explored the safety of intravenous thrombolysis (IVT) or intra-arterial treatment (IAT) in patients with ischemic stroke on non-vitamin K antagonist oral anticoagulants (NOACs, last intake <48 hours) in comparison with patients (1) taking vitamin K antagonists (VKAs) or (2) without previous anticoagulation (no-OAC). Methods and Results— This is a multicenter cohort pilot study. Primary outcome measures were (1) occurrence of intracranial hemorrhage (ICH) in 3 categories: any ICH (ICH any ), symptomatic ICH according to the criteria of the European Cooperative Acute Stroke Study II (ECASS-II) (sICH ECASS-II ) and the National Institute of Neurological Disorders and Stroke …

MaleBrain Ischemia/blood/drug therapyVitamin Kmedicine.medical_treatmentendovascular proceduresAnticoagulants/administration & dosage/adverse effects/classification/therapeutic useAdministration OralPilot ProjectsTissue plasminogen activatorBrain IschemiaCohort Studies2737 Physiology (medical)Atrial Fibrillation80 and overThrombolytic TherapyVitamin K/antagonists & inhibitorsStrokethrombolytic therapyAged 80 and overIncidenceAtrial fibrillationThrombolysisMiddle Aged3. Good healthvitamin K antagonistsTreatment OutcomeAdministrationAcute DiseaseCohortCerebral Hemorrhage/chemically induced/epidemiologyFemaleCardiology and Cardiovascular MedicineAtrial Fibrillation/complicationsmedicine.drugOralmedicine.medical_specialtyanticoagulantsnon-vitamin K antagonist oral anticoagulantsFactor Xa Inhibitors/administration & dosage/adverse effects/therapeutic useintracranial hemorrhagesintra-arterial treatment610 Medicine & healthAntithrombins2705 Cardiology and Cardiovascular MedicineDabigatranFibrinolytic AgentsPhysiology (medical)Internal medicinemedicineischemic strokeHumansAgedCerebral HemorrhageIntracerebral hemorrhageFibrinolytic Agents/therapeutic usebusiness.industryAntithrombins/administration & dosage/adverse effects/therapeutic usemedicine.diseaseddc:616.810040 Clinic for Neurologyanticoagulants; endovascular procedures; intra-arterial treatment; intracranial hemorrhages; ischemic stroke; non-vitamin K antagonist oral anticoagulants; thrombolytic therapy; vitamin K antagonistsPropensity score matchingbusinessFactor Xa InhibitorsCirculation
researchProduct

Intravenous Thrombolysis in Patients Dependent on the Daily Help of Others Before Stroke

2016

Background and Purpose— We compared outcome and complications in patients with stroke treated with intravenous thrombolysis (IVT) who could not live alone without help of another person before stroke (dependent patients) versus independent ones. Methods— In a multicenter IVT-register–based cohort study, we compared previously dependent (prestroke modified Rankin Scale score, 3–5) versus independent (prestroke modified Rankin Scale score, 0–2) patients. Outcome measures were poor 3-month outcome (not reaching at least prestroke modified Rankin Scale [dependent patients]; modified Rankin Scale score of 3–6 [independent patients]), death, and symptomatic intracranial hemorrhage. Unadjusted an…

Malemedicine.medical_treatment030204 cardiovascular system & hematologylaw.inventionCohort Studies0302 clinical medicineRandomized controlled triallawModified Rankin ScaleActivities of Daily Living80 and overThrombolytic TherapyRegistriesStrokeriskAged 80 and overpreexisting disabilityMedicine (all)survivorsThrombolysisMiddle Aged3. Good healthStrokeTreatment OutcomeInfusions intravenous; Intracranial hemorrhages; Outcome assessment (health care); Stroke; Survivors; Administration Intravenous; Aged; Aged 80 and over; Cohort Studies; Female; Humans; Logistic Models; Male; Middle Aged; Stroke; Treatment Outcome; Activities of Daily Living; Independent Living; Registries; Thrombolytic Therapy; Medicine (all); Neurology (clinical); Cardiology and Cardiovascular Medicine; Advanced and Specialized Nursingcontrolled-trialAdministration[SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]Administration IntravenousFemaleIndependent Livingacute ischemic-strokehemorrhageCardiology and Cardiovascular MedicineCohort studymedicine.medical_specialtyintracranial hemorrhagesstatinsscale03 medical and health sciencesInternal medicinemedicineHumansDementiaAgedoutcome assessment (health care)Advanced and Specialized Nursingreliabilitybusiness.industryOdds ratiomedicine.diseaseConfidence intervalinfusionsSurgeryLogistic Models[ SDV.NEU ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]intravenousiv thrombolysisNeurology (clinical)business030217 neurology & neurosurgeryStroke
researchProduct

Non-office-hours admission affects intravenous thrombolysis treatment times and clinical outcome

2018

In patients treated with intravenous thrombolysis (IVT), an unfavourable ‘non-office-hours effect’ on door-to-needle time (DNT) and clinical outcome has been suggested. This effect has been attributed to a number of factors, mostly related to either less efficient logistics or less (experienced) staffing during non-office hours (NH). These factors could result in longer DNTs and more protocol violations and thus in worse clinical outcome. On the other hand, one could also argue that the workload during NH is lower, which could result in less time delays in the various diagnostic processes and thus in better clinical outcome. Our hypothesis is that admission during NH has a negative effect o…

MaleTime delaysmedicine.medical_specialtyTime Factorsmedicine.medical_treatmentOutcome (game theory)Time-to-TreatmentCohort Studies03 medical and health sciences0302 clinical medicinePatient AdmissionModified Rankin ScaleIschaemic strokemedicineHumansThrombolytic Therapy030212 general & internal medicineStrokeAgedAged 80 and overbusiness.industryThrombolysisMiddle Agedmedicine.diseasestroke3. Good healthMechanical thrombectomyPsychiatry and Mental healthTreatment OutcomeEmergency medicineCohortPhysical therapySurgeryFemaleNeurology (clinical)business030217 neurology & neurosurgeryJournal of neurology, neurosurgery, and psychiatry
researchProduct

Association of prestroke metformin use, stroke severity, and thrombolysis outcome

2020

ObjectiveTo evaluate whether pretreatment with metformin (MET) is associated with less stroke severity and better outcome after IV thrombolysis (IVT), we analyzed a cohort of 1,919 patients with stroke with type 2 diabetes mellitus in a multicenter exploratory analysis.MethodsData from patients with diabetes and ischemic stroke treated with IVT were collected within the European Thrombolysis in Ischemic Stroke Patients (TRISP) collaboration. We applied propensity score matching (PSM) to obtain balanced baseline characteristics of patients treated with and without MET.ResultsOf 1,919 patients with stroke with type 2 diabetes who underwent IVT, 757 (39%) had received MET before stroke (MET+),…

Malemedicine.medical_specialtymedicine.medical_treatment610 Medicine & health030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineFibrinolytic AgentsModified Rankin ScaleInternal medicineDiabetes mellitusEpidemiologymedicineHumansHypoglycemic AgentsThrombolytic Therapycardiovascular diseases10064 Neuroscience Center ZurichStrokeAgedRetrospective Studiesbusiness.industryRecovery of Function10060 Epidemiology Biostatistics and Prevention Institute (EBPI)ThrombolysisMiddle Agedmedicine.diseaseMetformin10040 Clinic for Neurology3. Good healthMetforminStroke2728 Neurology (clinical)Diabetes Mellitus Type 2Propensity score matchingCohortFemaleNeurology (clinical)business030217 neurology & neurosurgerymedicine.drugNeurology
researchProduct